|
Synonyms: GSK3882347
Compound class:
Synthetic organic
Comment: Luxafimloc (also known as GSK3882347) is an orally bioavailable, mannose-containing small molecule with promising anti-virulence activity against uropathogenic Gram-negative bacteria. The chemical structure is claimed in GSK patent WO2020012336A1 [1] and was presented during the ACS Fall 2026 meeting's First Time Disclosures session [2].
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Luxafimloc is in clinical development as an oral treatment for uncomplicated urinary tract infections (uUTIs). Three separate Phase 1 studies have been completed, evaluating safety, tolerability, and pharmacokinetics in healthy volunteers (NCT04488770); potential drug-drug interactions (NCT05760261); and microbiological response in female participants with uUTIs (NCT05138822). Results from these studies have not been published in peer reviewed literature (September 2026). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05760261 | Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years | Phase 1 Interventional | GlaxoSmithKline | ||
| NCT05138822 | Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections | Phase 1 Interventional | GlaxoSmithKline | ||
| NCT04488770 | Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants. | Phase 1 Interventional | GlaxoSmithKline | ||